Entries tagged "Eli Lilly"

You have executed a tag search on The Deal Pipeline. Below, you will find a comprehensive list of stories tagged "Eli Lilly."

12 result(s) displayed (1 - 12 of 13)

The marriage of theory and practice

Abigail Barrow and Steven Shapin on the interaction of science, technology and economic development. Continue reading

Posted on May 15, 2009 11:59 AM

Dialoguing at Deutsche

Bruce Evans takes the reins of Deutsche's M&A effort at a difficult time. Continue reading

Posted on March 20, 2009 1:44 PM

The big trial

From VC to licensing, Exelixis has done every kind of deal to keep itself afloat, except one. Is an acquisition next? Continue reading

Posted on March 6, 2009 11:29 AM

Cravath helps Bristol feed a starved IPO market

Bristol-Myers plans to raise $500M-plus selling shares in Mead Johnson Nutrition Co. Cravath's Ronald Cami and Susan Webster are advising. Continue reading

Posted on February 6, 2009 1:15 PM

Out of rhythm

Boston Scientific snatched cardiac implant maker Guidant away from healthcare giant Johnson & Johnson three years ago and hasn't breathed easily since. Continue reading

Posted on January 23, 2009 12:56 PM

Winter's chill

Law firms struggle to cope with deal markets that have gone deathly quiet. The comparison: Silicon Valley after the dot-com bust. Continue reading

Posted on January 23, 2009 12:53 PM

Where dealmaking is healthy

Veteran healthcare dealmakers are moving to smaller firms, including Samantha Miller, who joined Jennerex Biotherapeutics. Continue reading

Posted on January 23, 2009 12:43 PM

They need a new drug

Expect Big Pharma to go shopping in biotechland, but with an eye for fire sales. Continue reading

Posted on January 9, 2009 2:10 PM

Lilly and Latham join forces again

Gibson Dunn's Anne Benedict advised United Therapeutics in its deal with Eli Lilly. Continue reading

Posted on December 1, 2008 2:10 PM

ImClone

Massachusetts' State-Boston Pension Fund has stepped in with a lawsuit to block Eli Lilly's $6.5 billion deal for ImClone. Continue reading

Posted on October 27, 2008 4:35 PM

Spread too far

Amid turmoil, risk arbs have absorbed a lot of bad news, but some strategic deals look likely to close, and deal demand may be building. Continue reading

Posted on October 17, 2008 3:34 PM

Latham gilds Lilly's ImClone offer

Deutsche Bank AG's Jim Stynes, Michael Cohen and Bruce Evans were among the financial advisers. Continue reading

Posted on October 10, 2008 12:35 PM

Movable Type search results powered by Fast Search